Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/GART_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/GART_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/GART_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/GART_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/GART_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/GART_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/GART_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000616312 | Liver | Cirrhotic | purine nucleotide metabolic process | 146/4634 | 396/18723 | 4.12e-08 | 1.34e-06 | 146 |
GO:19016051 | Liver | Cirrhotic | alpha-amino acid metabolic process | 82/4634 | 195/18723 | 7.72e-08 | 2.30e-06 | 82 |
GO:000652011 | Liver | Cirrhotic | cellular amino acid metabolic process | 103/4634 | 284/18723 | 8.88e-06 | 1.30e-04 | 103 |
GO:00091232 | Liver | Cirrhotic | nucleoside monophosphate metabolic process | 36/4634 | 76/18723 | 1.55e-05 | 2.11e-04 | 36 |
GO:004239811 | Liver | Cirrhotic | cellular modified amino acid biosynthetic process | 25/4634 | 46/18723 | 1.61e-05 | 2.19e-04 | 25 |
GO:00091121 | Liver | Cirrhotic | nucleobase metabolic process | 20/4634 | 34/18723 | 2.41e-05 | 3.14e-04 | 20 |
GO:000916111 | Liver | Cirrhotic | ribonucleoside monophosphate metabolic process | 29/4634 | 58/18723 | 2.87e-05 | 3.64e-04 | 29 |
GO:00090691 | Liver | Cirrhotic | serine family amino acid metabolic process | 22/4634 | 40/18723 | 4.04e-05 | 4.82e-04 | 22 |
GO:00463905 | Liver | Cirrhotic | ribose phosphate biosynthetic process | 71/4634 | 190/18723 | 7.09e-05 | 7.98e-04 | 71 |
GO:00091265 | Liver | Cirrhotic | purine nucleoside monophosphate metabolic process | 23/4634 | 44/18723 | 7.87e-05 | 8.61e-04 | 23 |
GO:000657511 | Liver | Cirrhotic | cellular modified amino acid metabolic process | 70/4634 | 188/18723 | 9.04e-05 | 9.69e-04 | 70 |
GO:00092605 | Liver | Cirrhotic | ribonucleotide biosynthetic process | 68/4634 | 182/18723 | 1.00e-04 | 1.05e-03 | 68 |
GO:00091654 | Liver | Cirrhotic | nucleotide biosynthetic process | 89/4634 | 254/18723 | 1.45e-04 | 1.40e-03 | 89 |
GO:19012934 | Liver | Cirrhotic | nucleoside phosphate biosynthetic process | 89/4634 | 256/18723 | 1.97e-04 | 1.82e-03 | 89 |
GO:00091675 | Liver | Cirrhotic | purine ribonucleoside monophosphate metabolic process | 21/4634 | 41/18723 | 2.32e-04 | 2.11e-03 | 21 |
GO:00091526 | Liver | Cirrhotic | purine ribonucleotide biosynthetic process | 62/4634 | 169/18723 | 3.52e-04 | 3.00e-03 | 62 |
GO:0046112 | Liver | Cirrhotic | nucleobase biosynthetic process | 11/4634 | 18/18723 | 1.13e-03 | 7.73e-03 | 11 |
GO:00725225 | Liver | Cirrhotic | purine-containing compound biosynthetic process | 69/4634 | 200/18723 | 1.22e-03 | 8.24e-03 | 69 |
GO:0006544 | Liver | Cirrhotic | glycine metabolic process | 10/4634 | 16/18723 | 1.51e-03 | 9.91e-03 | 10 |
GO:00061645 | Liver | Cirrhotic | purine nucleotide biosynthetic process | 65/4634 | 191/18723 | 2.42e-03 | 1.46e-02 | 65 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GART | SNV | Missense_Mutation | novel | c.2695N>A | p.Leu899Ile | p.L899I | P22102 | protein_coding | tolerated(0.07) | probably_damaging(0.987) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GART | SNV | Missense_Mutation | | c.667G>C | p.Glu223Gln | p.E223Q | P22102 | protein_coding | deleterious(0.01) | benign(0.179) | TCGA-BH-A1FC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GART | SNV | Missense_Mutation | | c.1193N>T | p.Ser398Leu | p.S398L | P22102 | protein_coding | tolerated(0.39) | benign(0.011) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GART | SNV | Missense_Mutation | | c.342N>A | p.Met114Ile | p.M114I | P22102 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GART | insertion | In_Frame_Ins | novel | c.1301_1302insCATACATATCCT | p.Ser434_Leu435insIleHisIleLeu | p.S434_L435insIHIL | P22102 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GART | deletion | Frame_Shift_Del | | c.3002delA | p.Asn1001MetfsTer14 | p.N1001Mfs*14 | P22102 | protein_coding | | | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GART | deletion | Frame_Shift_Del | rs777845343 | c.2420delA | p.Lys807ArgfsTer7 | p.K807Rfs*7 | P22102 | protein_coding | | | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
GART | SNV | Missense_Mutation | | c.1237G>A | p.Glu413Lys | p.E413K | P22102 | protein_coding | tolerated(0.33) | benign(0.012) | TCGA-C5-A8XJ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
GART | SNV | Missense_Mutation | | c.2488N>C | p.Glu830Gln | p.E830Q | P22102 | protein_coding | tolerated(0.26) | benign(0.006) | TCGA-JW-A852-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
GART | SNV | Missense_Mutation | | c.763N>A | p.Leu255Ile | p.L255I | P22102 | protein_coding | tolerated(0.1) | probably_damaging(0.947) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |